Cahill Logo

Andrew J. Cochran

Andrew J. Cochran


Download vCard

Cahill Gordon & Reindel LLP
32 Old Slip
New York, NY 10005



  • Fordham University School of Law, J.D., 2013
  • Ohio State University, M.S., 2008
  • Ohio State University, B.S., 2006


  • New York
  • U.S. Patent and Trademark Office
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Eastern District of Texas

Andrew (Andy) Cochran is counsel in the New York office of Cahill Gordon & Reindel LLP. While Andy has a versatile range of experience in high-stakes patent matters involving a variety of technologies, including enterprise content management software, enterprise file sharing and sync software, microchip technology, and medical devices, he focuses his practice mainly on complex patent litigation matters involving pharmaceuticals, biotechnology, and biologics/biosimilars both in federal court and before the Patent Trial and Appeal Board of the U.S. Patent Office. Andy also has an extensive patent prosecution background that has encompassed an array of technologies, including automotive hybrid systems, medical devices, consumer products, and oncology. Andy is a contributor to the “Intellectual Property Issues for Pharmaceutical Manufacturers” chapter in Fastcase’s Regulation of Pharmaceutical Manufacturers (2020). Andy was featured in the 2024 edition of Best Lawyers’ “Ones to Watch” in the area of patent litigation. 


  • Representing Galderma in Hatch-Waxman litigation relating to Oracea®, a once-daily doxycycline
    product used to treat rosacea
  • Representing an individual inventor in patent litigation involving a novel microchip
  • Represented large software company in competitor-vs-competitor, multi-district patent litigation on enterprise content management software*
  • Represented pharmaceutical company in BPCIA litigation regarding a biosimilar to monoclonal
    antibody product, Humira®*
  • Represented the patent owner in an inter partes review regarding a long-acting pharmaceutical
    product used to treat alcohol and opioid dependence*
  • Represented a pharmaceutical company in Hatch-Waxman litigation involving Entereg, an oral
    pharmaceutical product for the treatment of post-operative ileus*
  • Represented a pharmaceutical company in Hatch-Waxman litigation involving an extended-release
    product used to treat the gastrointestinal disorder, ulcerative colitis*

*Matter handled prior to joining Cahill.

Professional Activities:


  • New York Intellectual Property Law Association (NYIPLA)